March 29, 2021

Quantitative SARS-CoV-2 Anti-Spike Responses to Pfizer-BioNTech and Oxford-AstraZeneca Vaccines by Previous Infection Status

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): antibodies, vaccine

• [Pre-print, not peer-reviewed] Vaccination with either the Pfizer-BioNTech or Oxford-AstraZeneca vaccines led to detectable anti-spike antibodies in nearly all participants in a study of adult healthcare workers (HCWs) in the UK. 3570/3610 (98.9%) HCWs were seropositive >14 days post-first vaccination and prior to second vaccination, 2706/2720 (99.5%) after Pfizer-BioNTech and 864/890 (97.1%) following Oxford-AstraZeneca vaccines. HCWs who had previously been infected or were younger were more likely to test seropositive post-first vaccination, with no evidence of differences by sex or ethnicity, and all HCWs tested >14 days after the second vaccine were seropositive. Antibody responses post-second vaccination were similar to those after prior infection and one vaccine dose.

Eyre et al. (Mar 26, 2021). Quantitative SARS-CoV-2 Anti-Spike Responses to Pfizer-BioNTech and Oxford-AstraZeneca Vaccines by Previous Infection Status. Pre-print downloaded Mar 29 from https://doi.org/10.1101/2021.03.21.21254061